Provided by Tiger Trade Technology Pte. Ltd.

Incyte

127.81
+0.59000.46%
Post-market: 127.810.00000.00%19:30 EDT
Volume:1.37M
Turnover:175.38M
Market Cap:25.91B
PE:16.28
High:129.92
Open:126.45
Low:125.60
Close:127.22
52wk High:132.60
52wk Low:81.09
Shares:202.70M
Float Shares:169.82M
Volume Ratio:1.00
T/O Rate:0.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:4.08
PE(LYR):19.94

Loading ...

Wells Fargo Adjusts Price Target on Incyte to $116 From $101

MT Newswires Live
·
Jul 29

Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline

TIPRANKS
·
Jul 28

Movement Alert|Incyte Intraday Rise 5.24%, Q2 Earnings Significantly Beat Expectations with Full-Year Revenue Guidance Raised

Market Focus
·
Jul 28

Stock Track | Incyte Soars 5% in Intraday Trading on Q2 Earnings Beat and Raised Annual Revenue Guidance

Stock Track
·
Jul 28

Incyte Lifts Annual Revenue Forecast After Settlement with CMS

Reuters
·
Jul 28

Incyte Corp Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 28

Kiniksa Pharmaceuticals Q2 Product Revenue Rises on Arcalyst Sales

Reuters
·
Jul 28

Incyte Q2 Non-GAAP Earnings, Revenue Rise; Raises 2026 Sales Guidance

MT Newswires Live
·
Jul 28

Incyte Q2 Adj. EPS $3.09 Beats $2.12 Estimate, Sales $1.663B Beat $1.460B Estimate

Benzinga Earnings
·
Jul 28

Incyte Q2 Adjusted EPS USD 3.09 Vs. IBES Estimate USD 2.1

Reuters
·
Jul 28

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS
·
Jul 28

Corrected-Incyte Q2 Revenue USD 1,674 Million VS. Ibes Estimate USD 1,474 Million (Corrects Amount)

THOMSON REUTERS
·
Jul 28

Incyte Corp. Stock Underperforms Monday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 28

Cintas, KeyCorp, Butterfly Network, Conagra, Incyte Insider Shake-Up

TIPRANKS
·
Jul 25

Incyte is Maintained at Equal-weight by Morgan Stanley

Dow Jones
·
Jul 24

Incyte Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 23

Morgan Stanley Adjusts Price Target on Incyte to $104 From $103, Maintains Equalweight Rating

MT Newswires Live
·
Jul 22

Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), Immunome (IMNM) and Incyte (INCY)

TIPRANKS
·
Jul 22

Incyte: ENHANZE Licensing Bolsters INCA033989 Outlook as Buy Rating and $140 Price Target Are Reiterated

TIPRANKS
·
Jul 22

Incyte Price Target Maintained with a $140.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 21